SHARPIN is a key regulator of immune and inflammatory responses

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2271-2279

  Wang, Zhe ^a   Potter, Christopher S ^b   Sundberg, John P ^b   Hogenesch, Harm ^a  

^a PURDUE UNIVERSITY   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

Chronic dermatitis; Eosinophilic dermatitis; Immune system; Inflammation; Lymphoid organogenesis; NF B; Scaly skin disease; Sharpin; Ubiquitination

Indexed keywords

BETA1 INTEGRIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NERVE PROTEIN; SHARPIN; UBIQUITIN;

ANIMAL; ANIMAL MODEL; APOPTOSIS; ARTICLE; DERMATITIS; GENE EXPRESSION; GENETICS; HUMAN; INFLAMMATION; LYMPHOID TISSUE; METABOLISM; MUTATION; ORGANOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; ANTIGENS, CD29; APOPTOSIS; CYTOKINES; DERMATITIS; GENE EXPRESSION; HUMANS; INFLAMMATION; LYMPHOID TISSUE; MODELS, ANIMAL; MUTATION; NERVE TISSUE PROTEINS; NF-KAPPA B; ORGANOGENESIS; PHENOTYPE; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

MUS;

EID: 84866397566     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01574.x     Document Type: Article

References (74)

1. Lim S, Sala C, Yoon J, et al. Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol Cell Neurosci. 2001; 17: 385-97.
2. Rantala JK, Pouwels J, Pellinen T, et al. SHARPIN is an endogenous inhibitor of [beta]1-integrin activation. Nat Cell Biol. 2011; 13: 1315-24.
3. Lupas AN, Gruber M. The structure of alpha-helical coiled coils. Adv Protein Chem. 2005; 70: 37-78.
4. Grabbe C, Dikic I. Functional roles of ubiquitin-like domain (ULD) and ubiquitin-binding domain (UBD) containing proteins. Chem Rev. 2009; 109: 1481-94.
5. Kanayama A, Seth RB, Sun L, et al. TAB 2 and TAB 3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 2004; 15: 535-48.
6. Ikeda F, Deribe YL, Skanland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature. 2011; 471: 637-41.
7. Iwai K. Linear polyubiquitin chains: a new modifier involved in NFkappaB activation and chronic inflammation, including dermatitis. Cell Cycle. 2011; 10: 3095-104.
8. Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature. 2011; 471: 633-6.
9. HogenEsch H, Gijbels MJ, Offerman E, et al. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol. 1993; 143: 972-82.
10. Seymour RE, Hasham MG, Cox GA, et al. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 2007; 8: 416-21.
11. Gijbels MJ, HogenEsch H, Blauw B, et al. Ultrastructure of epidermis of mice with chronic proliferative dermatitis. Ultrastruct Pathol. 1995; 19: 107-11.
12. Gijbels MJ, Zurcher C, Kraal G, et al. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm). Am J Pathol. 1996; 148: 941-50.
13. HogenEsch H, Janke S, Boggess D, et al. Absence of Peyer's patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J Immunol. 1999; 162: 3890-6.
14. Gerlach B, Cordier SM, Schmukle AC, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011; 471: 591-6.
15. HogenEsch H, Torregrosa SE, Boggess D, et al. Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12. Eur J Immunol. 2001; 31: 734-42.
16. Wang Z, Sokolovska A, Seymour R, et al. SHARPIN is essential for cytokine production, NF-κB signaling, and induction of Th1 differentiation by dendritic cells. PLoS One. 2012; 7: e31809.
17. Elias JA, Homer RJ, Hamid Q, et al. Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol. 2005; 116: 497-500.
18. HogenEsch H, Dunham A, Seymour R, et al. Expression of chitinase-like proteins in the skin of chronic proliferative dermatitis (cpdm/cpdm) mice. Exp Dermatol. 2006; 15: 808-14.
19. Wenzel SE. Eosinophils in asthma - closing the loop or opening the door? N Engl J Med. 2009; 360: 1026-8.
20. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc. 2009; 6: 256-9.
21. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009; 129: 1878-91.
22. De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol. 2009; 129: 14-30.
23. Okpara N, Aswad B, Baffy G. Eosinophilic colitis. World J Gastroenterol. 2009; 15: 2975-9.
24. Blanchard C, Rothenberg ME. Basic pathogenesis of eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008; 18: 133-43; x.
25. Renninger ML, Seymour RE, Whiteley LO, et al. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice. Exp Dermatol. 2010; 19: 252-8.
26. Grabrucker AM, Schmeisser MJ, Schoen M, et al. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol. 2011; 21: 594-603.
27. Liang Y, Seymour RE, Sundberg JP. Inhibition of NF-kappaB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice. J Invest Dermatol. 2011; 131: 141-9.
28. Zak DE, Schmitz F, Gold ES, et al. Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. Proc Natl Acad Sci USA. 2011; 108: 11536-41.
29. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011; 12: 715-23.
30. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011; 12: 695-708.
31. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006; 25: 6758-80.
32. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132: 344-62.
33. Weih F, Caamano J. Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev. 2003; 195: 91-105.
34. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006; 25: 6717-30.
35. Haglund K, Dikic I. Ubiquitylation and cell signaling. EMBO J. 2005; 24: 3353-9.
36. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009; 458: 430-7.
37. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009; 33: 275-86.
38. Malynn BA, Ma A. Ubiquitin makes its mark on immune regulation. Immunity. 2010; 33: 843-52.
39. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 1996; 84: 853-62.
40. Winston JT, Strack P, Beer-Romero P, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999; 13: 270-83.
41. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001; 412: 346-51.
42. Varadan R, Assfalg M, Haririnia A, et al. Solution conformation of Lys63-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling. J Biol Chem. 2004; 279: 7055-63.
43. Zhang L, Blackwell K, Shi Z, et al. The RING domain of TRAF2 plays an essential role in the inhibition of TNFalpha-induced cell death but not in the activation of NF-kappaB. J Mol Biol. 2010; 396: 528-39.
44. Vince JE, Pantaki D, Feltham R, et al. TRAF2 must bind to cellular inhibitors of apoptosis for umor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem. 2009; 284: 35906-15.
45. Mahoney DJ, Cheung HH, Mrad RL, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA. 2008; 105: 11778-83.
46. Varfolomeev E, Goncharov T, Fedorova AV, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008; 283: 24295-9.
47. Bianchi K, Meier P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol Cell. 2009; 36: 736-42.
48. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ. 2010; 17: 14-24.
49. Ea CK, Deng L, Xia ZP, et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006; 22: 245-57.
50. Wong WW, Gentle IE, Nachbur U, et al. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ. 2010; 17: 482-7.
51. Wu CJ, Conze DB, Li T, et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol. 2006; 8: 398-406.
52. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004; 430: 694-9.
53. Haas AL. Linear polyubiquitylation: the missing link in NF-kappaB signalling. Nat Cell Biol. 2009; 11: 116-8.
54. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep. 2009; 10: 706-13.
55. Kirisako T, Kamei K, Murata S, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006; 25: 4877-87.
56. Haas TL, Emmerich CH, Gerlach B, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009; 36: 831-44.
57. Tokunaga F, Sakata S, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 2009; 11: 123-32.
58. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001; 107: 7-11.
59. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008; 263: 591-6.
60. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009; 9: 778-88.
61. Rahighi S, Ikeda F, Kawasaki M, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell. 2009; 136: 1098-109.
62. Hadian K, Griesbach RA, Dornauer S, et al. NF-kappaB essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF-kappaB activation. J Biol Chem. 2011; 286: 26107-17.
63. Makris C, Godfrey VL, Krahn-Senftleben G, et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell. 2000; 5: 969-79.
64. Schmidt-Supprian M, Bloch W, Courtois G, et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell. 2000; 5: 981-92.
65. Smahi A, Courtois G, Vabres P, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000; 405: 466-72.
66. Yamanaka K, Ishikawa H, Megumi Y, et al. Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2. Nat Cell Biol. 2003; 5: 336-40.
67. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996; 274: 784-7.
68. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996; 274: 787-9.
69. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999; 18: 6910-24.
70. Kim C, Ye F, Ginsberg MH. Regulation of integrin activation. Annu Rev Cell Dev Biol. 2011; 27: 321-45.
71. Margadant C, Monsuur HN, Norman JC, et al. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol. 2011; 23: 607-14.
72. Zhang Y, Wang H. Integrin signaling and function in immune cells. Immunology. 2012; 135: 268-75.
73. Jung J, Kim JM, Park B, et al. Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 2010; 340: 161-7.
74. He L, Ingram A, Rybak AP, et al. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 2010; 120: 2094-108.